An aggressive, experimental fat-destruction peptide. It works by cutting off blood supply to fat cells, starving them until they die. This is a targeted approach -- it goes after fat tissue specifically -- but it's still very much in the experimental stage.
Dosing
0.5-1 mg per kg of body weight subq every other day. Keep cycles short (2-4 weeks only) and monitor kidney function closely.
Benefit Profile
Published Research
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
Fatty Liver/Adipose Tissue Dual-Targeting Nanoparticles with Heme Oxygenase-1 Inducer for Amelioration of Obesity, Obesity-Induced Type 2 Diabetes, and Steatohepatitis.
Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes.
Epigenetic Age Acceleration in Adolescence Associates With BMI, Inflammation, and Risk Score for Middle Age Cardiovascular Disease.
A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.
Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".
Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium.
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.